AIDS MALIGNANCY CONSORTIUM

艾滋病恶性肿瘤协会

• 批准号: 6522322
• 负责人: Joseph A. Sparano
• 金额: $ 17.19万
• 依托单位: MONTEFIORE MEDICAL CENTER (BRONX, NY)
• 依托单位国家: 美国
• 财政年份: 1999
• 资助国家: 美国
• 起止时间: 1999-09-20 至 2004-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6522322
• 关键词: AIDS related neoplasm /cancer; AIDS therapy; Kaposi's sarcoma; central nervous system neoplasms; clinical research; clinical trials; cooperative study; human subject; human therapy evaluation; lymphoma; medical outreach /case finding; neoplasm /cancer therapy

This application for membership in the AIDS Malignancy Consortium is submitted by Dr. Joseph A. Sparano on behalf of Montefiore Medical Center (including the Moses Division and Weiler Division) and a consortium of four other institutions, including Jacobi Medical Center, North Central Bronx Hospital, Bronx Lebanon Hospital, and Long Island Jewish Medical Center. At Montefiore Medical Center (MMC) alone, 111 patients with HIV-associated malignancies have been enrolled on clinical trials under Dr. Sparano s direction over the past 8 years. The prevalence of HIV infection in the Bronx, the community served by five of the six hospitals in this consortium, is among the highest in the nation. Of the 1.2 million residents of the Bronx, it is estimated that about 30,000 are knowingly (16,000) or unknowingly (14,000) HIV- infected. This community is served not only by hospital-based HIV specialty care clinics, but also by over 30 community-based clinics affiliated with MMC or Bronx Lebanon Hospital (BLH). BLH also has an active community outreach program. Approximately 5900 patients receive primary HIV care by the consortium institutions. Moreover, among consortium institutions, it is estimated that each year there are approximately 110 patients newly diagnosed with HIV-associated and AIDS-associated cancers each year, including 46 patients wit systemic lymphoma, 14 patients with primary CNS lymphoma, and 50 patients with Kaposi s sarcoma. MMC has extensive experience in clinical trials in cancer and AIDS research. It is the University Hospital of the Albert Einstein College of Medicine (AECOM), and as such is the clinical arm of the NCI-designated Comprehensive Cancer Center at AECOM. Each year, over 100 clinical protocols are active, over 400 patients are enrolled on clinical trials, and about 55 percent of those enrolled on clinical trials are either African- American or Latino. MMC is also a member of the Eastern Cooperative Oncology Group. At ECOG s last audit of MMC s clinical trials performance and data management in 1997, MMC was rated as excellent to outstanding by ECOG. New York State- designated AIDS centers are based at MMC and BLH, and MMC, BLH, and Jacobi Medical Center participate in the CPCRA. MMC and its partners are therefore ideally suited to become productive members of AMC because of its large patient base, its considerable experience in cancer clinical trials, and the scientific leadership that has been demonstrated by its principal investigator.

约瑟夫·A·斯帕拉诺（Joseph A. Sparano）博士代表Montefiore医疗中心（包括摩西司和韦勒部门）和其他四个机构的财团，包括Jacobi医疗中心，包括Bronx Bronx North Bronx医院，Bronx Lebanon医院和长岛犹太人医疗中心。 在过去的8年中，仅在蒙特菲奥尔医疗中心（MMC），在Sparano博士的方向下，已在临床试验中招募了111例艾滋病毒相关的恶性肿瘤患者。 布朗克斯郡的艾滋病毒感染的患病率是该财团的六家医院中的五家社区，这是美国最高的。在布朗克斯的120万居民中，据估计，大约有30,000人是故意的（16,000）或不知不觉中（14,000）艾滋病毒感染。 该社区不仅由基于医院的HIV专业护理诊所提供服务，而且还由MMC或Bronx Lebanon医院（BLH）的30多个社区诊所提供服务。 BLH还拥有一个积极的社区外展计划。 大约有5900名患者接受了财团机构的初级艾滋病毒护理。 此外，在财团机构中，据估计，每年大约有110例新诊断为与HIV相关和与AIDS相关的癌症的患者，包括46例WIT系统性淋巴瘤，14例患有原发性CNS淋巴瘤患者，50例患有Kaposi sarcoma的患者。 MMC在癌症和艾滋病研究方面具有丰富的经验。 它是阿尔伯特·爱因斯坦医学院（AECOM）的大学医院，因此是AECOM的NCI指定综合癌症中心的临床部门。 每年，有100多种临床方案是活跃的，有400多名患者正在临床试验中，约有55％参加临床试验的患者是非裔美国人或拉丁裔。 MMC还是东方合作肿瘤学小组的成员。 在ECOG的最后一次对MMC的临床试验性能和数据管理的审计中，MMC被ECOG评为出色。 纽约州指定的艾滋病中心位于MMC和BLH，MMC，BLH和Jacobi医学中心参加CPCRA。 因此，MMC及其合作伙伴非常适合成为AMC的生产成员，因为其庞大的患者基础，在癌症临床试验中的丰富经验以及其首席研究员所证明的科学领导力。